Drugmaker VIVUS reported its fourth-quarter earnings after the closing bell on Monday. Shares traded down 12% today; investors were clearly not impressed with the results.
Sales of the company's obesity drug Qsymia were the primary focus of the report, but what else should investors be paying attention to when they analyze VIVUS' quarter? In this video, health care analyst Max Macaluso discusses three essential topics that investors need to consider.
Is now the time to sell VIVUS?
VIVUS' shares were clobbered after Qsymia's dismal launch. Investors everywhere are wondering whether the tide will turn for this fledgling drugmaker or if now is the perfect time to sell. In a new premium research report, the Fool's top health care contributor breaks down this complex story and explains the details VIVUS investors must know -- including reasons to buy and sell. To find out more about this premium report -- complete with a full year of free updates -- click here now.
The article 3 Key Takeaways From VIVUS' Earnings originally appeared on Fool.com.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.